The Sanviva Case Study: Operational and Regulatory Dynamics of Axcel’s Pan-European MedTech Distribution Consolidation

Nelson Advisors
2 hours ago
11 min read

The execution of private equity buy-and-build strategies within the highly fragmented European medical technology distribution sector has reached a new level of scale and complexity. On June 2nd 2026, Nordic private equity firm Axcel announced the simultaneous acquisition of four distinct regional distributors to establish Sanviva, a newly consolidated European medical device distribution network. By pulling Apodan (Denmark), PartnerMed (Norway), AllweCare Medical (Netherlands), and XboXLab (Sweden) into a unified platform, Axcel is building a single, pan-European gateway.

This consolidated platform, headquartered in Copenhagen, Denmark, establishes an immediate footprint across six European countries: Denmark, Sweden, Norway, Finland, Belgium and the Netherlands, operating with an initial workforce of approximately 60 employees.

The overarching strategy of the platform, under the leadership of newly appointed Group CEO Andreas von Scholten, is to act as a highly specialised local commercialisation partner for global medical device manufacturers and original equipment manufacturers (OEMs).

By providing direct access to multiple regional healthcare markets through a single partnership, Sanviva removes the need for OEMs to build out expensive, country-by-country sales forces or independently navigate local regulatory and public tendering frameworks.

Transaction Architecture and Private Equity Fund Dynamics

The consolidation of Sanviva was financed through Axcel Elevate I, a lower mid-market fund that held its final close at its oversubscribed hard cap of €459 Million in November 2025. This fund operates alongside Axcel’s larger mid-market vehicles, such as the €1.3 Billion Axcel VII fund, and specifically targets high-growth enterprises within the technology, business services, and healthcare sectors across Northern Europe.

The transaction was formally completed in March 2026, marking the platform's initial deployment alongside other early-stage fund investments such as the Norwegian financial technology firm KapitalKontroll.

Dimension	Details	Source
Sponsoring Private Equity Fund	Axcel Elevate I	Various
Fund Size & Closing	€459 Million (Closed at hard cap, November 2025)	Various
Transaction Completion Date	March 2026	Various
Formal Platform Launch Date	June 2, 2026	Various
Sponsoring Firm Total Capital	Over €4.8 billion raised across nine funds since inception	Various
Fundraising Advisory	PJT Park Hill (Global Advisor), Kirkland & Ellis (Legal Counsel)	Various
Lead Transaction Counsel	Vinge (M&A, FDI, and Corporate Commercial teams)	Various
Operating Executive Leadership	Andreas von Scholten (Group CEO, ex-Coloplast, Zoetis, Grobest)	Various

The organisational leadership of the Elevate fund includes Christian Schmidt-Jacobsen, who has served as Axcel's Managing Partner since 2016 and retains direct responsibility for the Elevate strategy. This operates in parallel with a wider leadership transition within the firm, which saw Christian Bamberger Bro assume the role of Managing Partner in the first half of 2026.

The execution of the Elevate investment mandate was further strengthened by the addition of Johan Lundén as a Swedish-based Partner in Spring 2026, bringing fifteen years of private equity experience from Trill Impact and Nordic Capital. The transaction team for the Sanviva platform also included Partners Kasper Olesen and Jacob Drakenberg Walberg, who actively led the deal execution.

On the transaction advisory side, the Swedish business law firm Vinge acted as the primary legal advisor to Axcel. Vinge deployed a multidisciplinary team led by M&A specialists Christina Kokko, Egil Svensson, Ida Appelgren, Manon de Cooman, and Lina Björkman.

Corporate commercial guidance was provided by Christoffer Nordin, while regulatory clearances under increasingly stringent Foreign Direct Investment (FDI) regimes were managed by Dagne Sabockis and Julia Rydin, with logistical transaction support coordinated by Filippa Bergkvist.

Comprehensive Profiles of the Acquired Entities

The foundational strength of Sanviva is derived from the distinct geographic footprints, commercial relationships, and specialized capabilities of the four consolidated distributors. Each target represents a localised market leader with historical roots in its respective domestic territory.

Acquired Company	Core Geography	Operational Scale	Specialized Product Portfolio	Key Regulatory & Logistics Assets	Sources
Apodan A/S	Denmark	14 employees; Est. $5.9M revenue	Wound care, compression systems, hygiene, diagnostics	DS/EN ISO 13485 certified; MDR compliant; Hørsholm office	Various
PartnerMed AS	Norway	~10 employees	Wound care, disinfection, hygiene consumables	Licensed pharmaceutical wholesaler; Fredrikstad HQ	Various
AllweCare Medical B.V.	Netherlands	11–20 employees; Est. $1.45M–$5.7M revenue	Ostomy care (LaproCare), silicone scar dressings (ScarView)	EUDAMED SRN NL-MF-000004379; Heteren facility	Various
XboXLab AB	Sweden	~15 employees	In vitro diagnostics (IVD), molecular and point-of-care testing	Gothenburg 3PL (Medical Log Point); NSG technical partnership	Various

Apodan A/S

Apodan A/S was founded in Kastrup, Denmark, by John Andreasen, initially importing and distributing active pharmaceutical ingredients to Danish pharmacies that manufactured localised medicines. In the 1970s, the company expanded into pharmaceutical packaging, subsequently establishing the Apodan PharmaPackaging brand to supply pill jars, vials and containers across the Nordic region.

Following ownership by the Vind family and a small group of employees in the mid-1990s, the current owner Morten Lodberg Petersen joined the company in January 1997, overseeing a generational transition and the acquisition of moving aid manufacturer Immedia A/S in 1998.

Apodan relocated to Hørsholm, Denmark, in 2017, and has focused its modern business model on four core areas: patient and surface hygiene products, specialised wound care, compression therapy systems, and clinical diagnostic equipment.

The firm holds DS/EN ISO 13485 quality certification, is fully compliant with the European Medical Devices Regulation (MDR) and operates with a highly specialised team of 14 employees, including registered nurses and engineers, generating estimated annual revenues of $5.9 Million. During the COVID-19 pandemic, Apodan acted as a critical supply partner to the Danish national healthcare system by delivering diagnostic tests and medical hygiene consumables.

PartnerMed AS

PartnerMed AS was incorporated in Norway in June 1998, operating from its corporate headquarters in Fredrikstad. The company is led by CEO Trine-Lise Setterberg Andersen alongside Operations Manager Lasse Setterberg Andersen and Business Process Manager Siri Risvik Engen.

PartnerMed acts as an authorised wholesale distributor of medical and pharmaceutical goods, specialising in wound care supplies, hospital disinfection systems, and clinical hygiene products. The company maintains a lean operational structure of approximately ten employees. It has built deep commercial penetration within Norwegian public hospitals, municipal nursing homes, and clinical practices, navigating the highly centralised public purchasing channels of the Norwegian state.

AllweCare Medical B.V

Operating from Heteren in the Gelderland region of the Netherlands, AllweCare Medical B.V. was founded in 2014, with its manufacturing arm, AwC Manufacturing B.V., established in 2016. Led commercially by Marketing Director Ton Mulder, the company employs between 11 and 20 staff, with annual revenues estimated between $1.45 Million and $5.7 Million.

AllweCare represents a key strategic asset for the Sanviva platform due to its integrated manufacturing capabilities, holding registered manufacturer status under EUDAMED Actor ID NL-MF-000004379.

The company's proprietary product lines include ScarView, a broad portfolio of medical-grade silicone dressings and gels designed to treat hypertrophic and keloid scars, alongside LaproCare, a specialised range of ostomy pouches and related accessories. AllweCare’s commercial channels span both high-volume business-to-business distribution and direct-to-consumer pharmacy reimbursement networks in the Benelux region.

XboXLab AB

XboXLab AB was established in Höllviken, Sweden, in 2016 by Peter Blom and Christer Lidén, who both brought over thirty years of clinical laboratory distribution experience to the venture. The firm expanded its operational footprint by launching a Norwegian subsidiary (XboXLab AS) under Managing Director Henning Jansen in 2019, and a Finnish subsidiary (XboXLab Oy) under Managing Director Jussi Kontturi in 2020.

In 2020, the group also acquired Medic24, a specialised Nordic point-of-care (POC) diagnostics business. XboXLab operates a highly efficient, asset-light business model utilising specialised external partners. Its physical logistics are outsourced to Medical Log Point, which provides 1,250 square meters of modern warehouse space, including 310 square meters of specialized cold storage in Gothenburg, Sweden.

For technical equipment maintenance, calibration, and support, XboXLab partners with Nordic Service Group, which deploys over 75 field engineers across the Nordic countries. XboXLab’s clinical focus covers in vitro diagnostics (IVD), immunohematology, immunology, molecular biology, and point-of-care testing systems, monitoring public laboratory tenders daily across Sweden, Norway, and Finland.

Regulatory Frameworks and Market Access Barriers

The consolidation of Sanviva is a direct response to rising regulatory demands and market access barriers across the European healthcare sector. The European medical technology market is valued at billions of euros, with healthcare spending averaging approximately 10% of gross domestic product (GDP) across European Union member states and per capita spending on medical technologies reaching €319 in recent years. However, capturing this market has become increasingly difficult for standalone, country-specific distributors.

The primary barrier to entry is the ongoing transition to the European Medical Devices Regulation (MDR 2017/745) and the In Vitro Diagnostic Medical Devices Regulation (IVDR 2017/746). These regulations divide medical devices and diagnostic tests into four distinct risk categories. They impose strict requirements regarding clinical evaluation reports, continuous post-market surveillance, EUDAMED registration, and complete supply chain traceability.

For global OEMs, particularly those based in the United States or Asia, complying with these requirements requires a local authorised representative and extensive administrative resources. Even with a valid CE mark, manufacturers cannot freely distribute devices without navigating country-specific rules. For example, in Belgium, any medical device distribution requires formal notification to the Federal Agency for Medicines and Health Products (FAGG-AFMPS), alongside strict customs clearances requiring physical declarations of conformity and batch certifications.

For a small distributor operating with fewer than twenty employees, the cost of employing dedicated regulatory officers to manage these requirements across multiple jurisdictions can quickly erode operating margins. By consolidating under the Sanviva platform, the acquired entities can centralise their regulatory and compliance departments. This allows them to spread compliance costs over a much larger revenue base, while offering global OEMs a single, fully compliant partner across the Nordics and Benelux regions.

The Tendering and Public Procurement Matrix in Northern Europe

Public procurement is the dominant purchasing mechanism in European healthcare, with approximately 70% of all medical devices and technologies bought through formal public tenders. However, the actual execution of these tenders is highly decentralised and fragmented by country and region.

[Global OEM Partners] 
       │
       ▼  (Single Commercial & Regulatory Agreement)
 ┌───────────┐
 │  SANVIVA  │ (Centralized Corporate HQ - Copenhagen, Denmark)
 └─────┬─────┘
       ├───────────────────────┬───────────────────────┐
       ▼                       ▼                       ▼
 ┌───────────┐           ┌───────────┐           ┌───────────┐
 │  NORDICS  │           │  BENELUX  │           │ REGULATORY│
 └─────┬─────┘           └─────┬─────┘           └─────┬─────┘
       ├─ Sweden (21 Regions)  ├─ NL (GVS System)      └─ MDR / IVDR
       ├─ Norway (Sykehusinn.) └─ BE (INAMI/RIZIV)        Compliance &
       ├─ Denmark (Amgros)                                FAGG Notification
       └─ Finland (21 Counties)

In Sweden, hospital procurement is divided across 21 independent regional authorities, alongside joint government framework agreements managed by the Kammarkollegiet via avropa.se. In Norway, public healthcare purchasing is centralized under Sykehusinnkjøp HF. This requires strict compliance with the national Doffin electronic database managed by the Norwegian Digitalisation Agency, which mandates public advertising for all tenders valued above NOK 1.4 million (~€120,000).

In Finland, the landmark 2023 healthcare reform shifted public purchasing power to 21 regional wellbeing services counties, utilising platforms like Hilma and Hanki. In Denmark, purchasing is managed by five regional procurement bodies alongside Amgros, the central procurement agency for the country's public hospitals.

Further west, the Belgian and Dutch markets present their own reimbursement and tendering complexities. In Belgium, the National Institute for Health and Disability Insurance (INAMI/RIZIV) maintains a strict list of reimbursable implants and invasive devices. This list requires brand-specific registration on "nominative lists" for high-cost devices, such as aortic valves, neuromodulation, and cardiovascular implants.

Belgian public tendering is governed by strict financial thresholds: any purchase exceeding €200,000 requires a full European tender published in the Official Journal of the European Union, while purchases between €85,000 and €200,000 must be published in the Belgian Official Journal.

In the Netherlands, outpatient devices and medicines are reimbursed through the complex Medicine Reimbursement System (GVS) managed by Zorginstituut Nederland. Additionally, individual Dutch university medical centres, such as Amsterdam UMC, Radboudumc, and LUMC, frequently run their own competitive tenders for medical equipment and consumables.

Compounding this fragmentation is the rise of cross-border purchasing alliances. The Nordic Pharmaceutical Forum (NPF), established in 2015 by Amgros, represents Denmark, Norway, Sweden, Finland and Iceland. The NPF is actively working to establish joint purchasing mechanisms and integrate environmental sustainability criteria into tenders.

Similarly, the BeNeLuxA alliance (comprising Belgium, the Netherlands, Luxembourg, Austria, and Ireland) has demonstrated the power of joint negotiations. This was highlighted by its collective pricing agreement for high-cost gene therapies like Zolgensma.

For clinical suppliers, these shifting dynamics require a deep understanding of local tendering rules and platforms. Sanviva’s strategy is designed to address this challenge directly. By maintaining dedicated, local commercial teams in each country, the network can manage local relationships and monitor national tendering databases daily. At the same time, it can leverage its collective scale to meet the sustainability, security of supply, and clinical criteria demanded by modern public healthcare buyers.

Platform Synergies and Value Creation Playbook

The private equity investment playbook deployed by Axcel Elevate I relies on clear levers of operational optimisation, synergy extraction, and commercial expansion. Rather than acting as a passive holding company, Sanviva is designed to operate as an integrated platform.

Portfolio Cross-Fertilisation and Cross-Selling

The primary commercial growth driver is the immediate cross-selling of proprietary and exclusive product lines across the combined geographic network. Historically, AllweCare’s high-margin ostomy (LaproCare) and scar therapy (ScarView) portfolios were commercially confined to the Benelux region. Following the merger, these proprietary product lines can be introduced directly into the Nordic markets using Apodan's established clinical relationships in Denmark, PartnerMed’s networks in Norway, and XboXLab’s multi-country sales channels.

Conversely, XboXLab’s sophisticated in vitro diagnostics and point-of-care testing systems can be integrated into AllweCare's existing distribution channels in the Netherlands and Belgium, introducing a high-growth clinical segment to those regions.

Logistic Integration and Shared Services

By merging four separate administrative and logistics networks, Sanviva can achieve significant cost savings. The platform's back-office functions—such as finance, human resources, regulatory compliance, IT, and legal advisory—can be centralised at the Copenhagen headquarters.

On the logistics front, the platform can optimise its warehousing by consolidating regional inventories. XboXLab’s existing partnership with Medical Log Point in Gothenburg, which features over 1,250 square meters of modern warehousing and 310 square meters of specialised cold storage, provides an ideal logistical hub for the Nordic countries.

Consolidating shipping volumes, standardising third-party logistics (3PL) contracts, and establishing shared cold-chain protocols reduces overall transportation costs and mitigates supply chain disruptions.

Professionalising the Tender Management Engine

Winning public tenders in Northern Europe is an administrative-heavy process that requires daily monitoring, specialised legal knowledge, and precise bid preparation. Individually, the acquired companies relied on small, localised teams to monitor platforms like Doffin (Norway), Hilma (Finland) and TendSign (Sweden).

Sanviva can build a centralised tender management office equipped with dedicated bid writers and legal experts. This centralized team can analyze historical tender data, optimise pricing structures and draft highly compliant, value-based tender responses.

Meanwhile, local representatives in each country, such as Apodan’s specialised nurses and clinical sales staff, can focus entirely on maintaining relationship touch points with hospital procurement officers and clinicians. This structure balances centralised bidding capabilities with necessary local market presence.

Strategic Outlook and Future Expansion

The launch of Sanviva by Axcel is a clear example of the ongoing professionalisation within the European medical device distribution sector. By executing a simultaneous quadruple acquisition through the Axcel Elevate I fund, the firm has quickly built a platform capable of handling the regulatory, logistical, and commercial complexities of modern healthcare markets.

The strategic logic of the transaction is highly aligned with the current macroeconomic and regulatory trends in Europe, where the rising cost of MDR/IVDR compliance and the shift toward Value-Based Procurement favour large, integrated players over small, regional distributors.

Looking ahead, Sanviva is well-positioned for further expansion. Having secured strong footholds in the highly stable and profitable Nordic and Benelux regions, the platform is likely to pursue additional bolt-on acquisitions. Strategic expansion into the DACH region (Germany, Austria, Switzerland), France, or the UK would further strengthen Sanviva’s value proposition to global medical device OEMs. By offering these OEMs a single, compliant and highly effective partner across the European continent, Sanviva is positioned to become a dominant pan-European force in MedTech distribution.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech